STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. ReFocus 2023, 2 (1), 11-19. https://doi.org/10.66073/researchfocus.v2i1.2819.